CSS logo
Computing and Software Systems       University of Washington, Bothell   

Howbert
                picture

J. Jeffry Howbert, Ph.D.

Affiliate Professor   Computing & Software Systems, University of Washington Bothell
Research Scientist   Department of Genome Sciences, University of Washington Seattle

PUBLICATIONS
  1. Computing exact p-values for a cross-correlation shotgun proteomics scoring function. JJ Howbert and WS Noble. (submitted).
  2. Fast exact counting of graph cycles C6 to C9 using powers of the adjacency matrix.  JJ Howbert. (submitted).
  3. Forecasting seizures in dogs with naturally occurring epilepsy. JJ Howbert, EE Patterson, SM Stead, V Vasoli, D Crepeau, CH Vite, B Sturges, V Ruedebusch, J Mavoori, K Leyde, WD Sheffield, B Litt, and GA Worrell. PLOS ONE (accepted).
  4. Identifying the structural architecture of the human inferior parietal lobule using diffusion MRI.  RF Tungaraza, JJ Howbert, SH Mehta, DR Haynor, LG Shapiro, and TJ Grabowski.  IEEE International Symposium on Biomedical Imaging, Barcelona, Spain, 2012, pp. 506-50.
  5. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.  H Lu, GN Dietsch, MH Matthews, Y Yang, S Ghanekar, M Inokuma, M Suni, VC Maino, KE Henderson, JJ Howbert, ML Disis, and RM Hershberg.  Clin. Cancer Res. 18: 499, 2012.
  6. MR-Tandem: Parallel X!Tandem using Hadoop MapReduce on Amazon Web Services.  B Pratt, JJ Howbert, NI Tasman, and EJ Nilsson.  Bioinformatics 28: 136, 2012.
  7. Identification of TNF-alpha inhibitors from a split-pool library based on a tyrosine-proline peptidomimetic scaffold.  RW Jackson, JC Tabone, and JJ Howbert.  Bioorg. Med. Chem. Lett. 13: 205, 2003.
  8. Benzobicyclooctanes as novel inhibitors of TNF-alpha signaling.  RW Jackson, R Gelinas, TA Baughman, T Cox, JJ Howbert, KA Kucera, JA Latham, F Ramsdell, D Singh, and IS Darwish.  Bioorg. Med. Chem. Lett. 12: 1093, 2002.
  9. Insights from model systems.  Of monkeys and men: vervets and the genetics of human-like behaviors.  RM Palmour, J Mulligan, JJ Howbert, and F Ervin.  Am. J. Hum. Genet. 61: 481, 1997.
  10. [3H]LY303870, a novel nonpeptide radioligand for the NK-1 receptor.  DR Gehlert, DA Schober, PA Hipskind, BD Gitter, and JJ Howbert.  J. Neurochem. 66: 1095, 1996.
  11. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.  PA Hipskind, JJ Howbert, RF Bruns, SSY Cho, TA Crowell, MM Foreman, DR Gehlert, S Iyengar, KW Johnson, JH Krushinski, DL Li, KL Lobb, NR Mason, BS Muehl, JA Nixon, LA Phebus, D Regoli, RM Simmons, PG Threlkeld, DC Waters, and BD Gitter.  J. Med. Chem. 39: 736, 1996.
  12. Pharmacological characterization of LY303870: a novel, potent, and selective non-peptide substance P (neurokinin-1) receptor antagonist.  BD Gitter, RF Bruns, JJ Howbert, DC Waters, PG Threlkeld, LM Cox, JA Nixon, KL Lobb, NR Mason, PW Stengel, SL Cockerham, SA Silbaugh, DR Gehlert, DA Schober, S Iyengar, DO Calligaro, D Regoli, and PA Hipskind.  J. Pharm. Exp. Therap. 275: 737, 1995.
  13. Practical and enantiospecific synthesis of LY303870, a novel NK-1 antagonist.  PA Hipskind, JJ Howbert, S Cho, JS Cronin, SL Fort, FO Ginah, GJ Hansen, BE Huff, KL Lobb, MJ Martinelli, AR Murray, JA Nixon, MA Staszak, and JD Copp.  J. Org. Chem. 60: 7033, 1995.
  14. The discovery of a novel class of potent, non-peptide substance P (NK-1) receptor antagonists.  PA Hipskind, JJ Howbert, L Phebus, R Bruns, SS Cho, TA Crowell.  Pharmacol. Toxicol. 76: S14, 1995.
  15. (R)-Thionisoxetine, a potent and selective inhibitor of central and peripheral norepinephrine uptake.  DR Gehlert, SK Hemrick-Luecke, DA Schober, J Krushinski, JJ Howbert, DW Robertson, DT Wong, and RW Fuller.  Life Sciences 56: 1915, 1995.
  16. Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain.  DR Gehlert, DA Schober, SK Hemrick-Luecke, J Krushinski, JJ Howbert, DW Robertson, RW Fuller, and DT Wong.  Neurochem. Internat. 26: 47, 1995.
  17. Interleukin-6 secretion from human astrocytoma cells induced by substance P.  BD Gitter, D Regoli, JJ Howbert, AL Glasebrook, and DC Waters.  J. Neuroimmunol. 51: 101, 1994.
  18. Inhibition of A9 and A10 dopamine cells by the cholecystokinin-B antagonist LY262691: mediation through feedback pathways from forebrain sites.  K Rasmussen, JJ Howbert, and ME Stockton.  Synapse, 15: 95, 1993.
  19. Use of non-peptide tachykinin receptor antagonists to substantiate the involvement of NK1 and NK2 receptors in a spinal nociceptive reflex in the rat.  P Picard, S Boucher, D Regoli, BD Gitter, JJ Howbert, and R Couture.  Eur. J. Pharmacol. 232: 255, 1993.
  20. Tachykinin receptor antagonists inhibit hyperpnea-induced bronchoconstriction in guinea pigs.  J Solway, BM Kao, JE Jordan, B Gitter, IW Rodger, JJ Howbert, LE Alger, J Necheles, AR Leff, and A Garland.  J. Clin. Invest. 92: 315, 1993.
  21. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys and dogs.  WJ Ehlhardt, HR Sullivan, PG Wood, JM Woodland, M Hamilton, C Hamilton, D Cornprobst, GB Grindey, JF Worzalla, JR Bewley, GC Todd, and JJ Howbert.  J. Pharmaceut. Sci. 82: 683, 1993.
  22. Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: a case of convergent evolution in medicinal chemistry.  JJ Howbert, KL Lobb, TC Britton, NR Mason, and RF Bruns.  Bioorg. Med. Chem. Lett. 3: 875, 1993.
  23. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.  K Rasmussen, JF Czachura, ME Stockton, and JJ Howbert.  J. Pharm. Exp. Therap. 264: 480, 1993.
  24. Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas.  WJ Ehlhardt, JM Woodland, JF Worzalla, JR Bewley, GB Grindey, GC Todd, JE Toth, and JJ Howbert.  Chem. Res. Toxicol. 5: 667, 1992.
  25. A novel series of non-peptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism.  JJ Howbert, KL Lobb, RF Brown, JK Reel, DA Neel, NR Mason, LG Mendelsohn, JP Hodgkiss, and JS Kelly.  In Multiple Cholecystokinin Receptors in the CNS; CT Dourish, SJ Cooper, SD Iversen, and LL Iversen, Eds.; Oxford University Press: London, 1992, 28-37.
  26. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.  BL Neubauer, RL Merriman, KL Best, RL Goode, MF Sarosdy, LR Tanzer, and JJ Howbert.  J. Urology 147: 500, 1992.
  27. Cholecystokinin (CCK) and schizophrenia: the selective CCK-B antagonist LY262691 decreases midbrain dopamine unit activity.  K Rasmussen, ME Stockton, JF Czachura, and JJ Howbert.  Eur. J. Pharmacol. 209: 135, 1991.
  28. Sulofenur.  JJ Howbert.  Monograph in: Drugs Future 16: 517, 1991.
  29. Species differences in affinities of nonpeptide antagonists for substance P receptors.  BD Gitter, DC Waters, RF Bruns, NR Mason, JA Nixon, and JJ Howbert.  Eur. J. Pharmacol. 197: 237, 1991.
  30. Selectivity and specificity of new, non-peptide, quinuclidine antagonists of substance P.  N Rouissi, BD Gitter, DC Waters, JJ Howbert, JA Nixon, and D Regoli.  Biochem. Biophys. Res. Comm. 176: 894, 1991.
  31. Inhibition of protein kinase C by calphostin C is light-dependent.  RF Bruns, FD Miller, RL Merriman, JJ Howbert, WF Heath, E Kobayashi, I Takahashi, T Tamaoki, and H Nakano.  Biochem. Biophys. Res. Comm. 176: 288, 1991.
  32. Metabolism and disposition of p-chloroaniline in rat, mouse, and monkey.  WJ Ehlhardt and JJ Howbert.  Drug Metab. Dispos. 19: 366, 1991.
  33. Synthesis of N-(1-keto-) and N-(1-hydroxy-5-indansulfonyl)-N'-(4-chlorophenyl)urea, two major metabolites of the antitumor agent sulofenur (LY186641).  JJ Howbert and TA Crowell.  Synthetic Comm. 20: 3193, 1990.
  34. Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.  JJ Howbert, CS Grossman, TA Crowell, BJ Rieder, RW Harper, KE Kramer, EV Tao, J Aikens, GA Poore, SM Rinzel, GB Grindey, WN Shaw, and GC Todd.  J. Med. Chem. 33: 2393, 1990.
  35. Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human colon adenocarcinoma cells.  PJ Houghton, FC Bailey, JA Houghton, KG Murti, JJ Howbert, and GB Grindey.  Cancer Res. 50: 664, 1990.
  36. Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea.  PJ Houghton, FC Bailey, GS Germain, GB Grindey, JJ Howbert, and JA Houghton.  Biochem. Pharmacol. 39: 1187, 1990.
  37. Evaluation of N-5-(indanylsulfonyl)-N'-(4-chlorophenyl)urea against xenografts of pediatric rhabdomyosarcoma.  PJ Houghton, JA Houghton, L Myers, PJ Cheshire, JJ Howbert, and GB Grindey.  Cancer Chemother. Pharmacol. 26: 84, 1989.
  38. Potent inhibition of interleukin 1b-mediated human melanoma (A375.6) lysis by corticosteroids, staurosporine, and tilorone.  RM Schultz, JJ Howbert, and RA Archer.  Immunopharmacol. Immunotoxicol. 11: 489, 1989.
  39. Synthetic studies on areneolefin cycloadditions -VI- two syntheses of (+-)-coriolin.  PA Wender and JJ Howbert.  Tetrahedron Lett. 5325, 1983.
  40. Synthetic studies on areneolefin cycloadditions -III- total synthesis of (+-)-hirsutene.  PA Wender and JJ Howbert.  Tetrahedron Lett. 3983, 1982.
  41. Synthetic studies on areneolefin cycloadditions: total synthesis of (+-)-cedrene.  PA Wender and JJ Howbert.  J. Am. Chem. Soc. 103: 688, 1981.
  42. Derivatives of trifluorovinylsulfur pentafluoride (SF5CF=CF2) - II.  R DeBuhr, J Howbert, JM Canich, HF White, and GL Gard.  J. Fluorine Chem. 20: 515, 1982.
POSTERS AND ABSTRACTS
  1. Continuous intracranial EEG recording and seizure forecasting in dogs with naturally occurring epilepsy. EE Patterson, JJ Howbert, SM Stead, V Vasoli, D Crepeau, CH Vite, B Sturges, V Ruedebusch, LD Coles, J Mavoori, K Leyde, WD Sheffield, B Litt, and GA Worrell. 3rd International Conference on Medical Bionics, Philip Island, Victoria, Australia, Nov. 17-20, 2013.
  2. Progress on development of neurophysiologically-based responsive therapy in dogs with naturally occurring epilepsy. G Worrell, E Patterson , C Vite, M Bower, V Vasoli, B Sturges, V Ruedebusch, L Coles, J Cloyd, B Brinkmann, M Stead, D Crepeau, J McDonnell, J Mavoori, J Howbert, K Leyde, D Sheffield, and B Litt. American Epilepsy Society, San Diego, CA, Nov. 30-Dec. 4, 2012.
  3. MR-Tandem: Parallel X!Tandem Using Hadoop MapReduce on Amazon Web Services.  BS Pratt, JJ Howbert, NI Tasman, and EJ Nilsson.  2011 Cascadia Proteomics Symposium, Seattle, WA, July 17-19, 2011.
  4. Synthesis of cleavable mass spectrometry tags: a system for SNP genotyping.  J Mathis, B Erwin, D Galas, L Garrison, E Keeler, J Howbert, M Kokoris, C Lock, K Moynihan, J Van Ness, B Skead, and J Tabone.  3rd Lake Tahoe Symposium on Molecular Diversity, Lake Tahoe, CA, Jan. 24-29, 1999.
  5. Synthesis of cleavable mass spectrometry tags: a system for SNP genotyping.  J Mathis, B Erwin, D Galas, L Garrison, E Keeler, J Howbert, M Kokoris, C Lock, K Moynihan, J Van Ness, B Skead, and J Tabone.  3rd Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, Jan. 23-29, 1999.
  6. Characterization of guinea pig NK1 receptors using the potent antagonist ligand, [3H]LY303870  DR Gehlert, DA Schober, PA Hipskind, J Nixon, BD Gitter, and JJ Howbert.  Soc. Neurosci. Abstr. 21:  , 1995.
  7. Pharmacological characterization of LY303870: a novel, potent, and selective non-peptide substance P receptor antagonist.  BD Gitter, RF Bruns, JJ Howbert, PW Stengel, DR Gehlert, S Iyengar.  Soc. Neurosci. Abstr. 21:  , 1995.
  8. Part I.  Antitubercular agents from higher plants: synthesis and in vivo activity of indigo[2,1b]-quinazoline-6,12-diones and related analogs.  WR Baker, LA Mitscher, B Feng, S Cai, M Clark, T Leung, JA Towell, I Darwish, J Howbert, K Stover, A Resconi, TM Arain, et al.  35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, Abstract F16, Sept. 1995.
  9. The discovery of LY303870, a novel and potent non-peptide substance P (NK-1) receptor antagonist with a long duration of action.  PA Hipskind, RF Bruns, DR Gehlert, JJ Howbert, S Iyengar, LA Phebus.  AFMC International Medicinal Chemistry Symposium/AIMECS 95, Tokyo, Japan, Sept. 3-8, 1995.
  10. The discovery of a novel class of potent, non-peptide substance P (NK-1) antagonists.  PA Hipskind, JJ Howbert, L Phebus, R Bruns, SS Cho, TA Crowell, KW Johnson, KL Lobb, JH Krushinski, NR Mason, BS Muehl, JA Nixon, PG Threlkeld, DC Waters, and BD Gitter.  5th Annual European Neuropeptide Meeting, Lund, Sweden, June 3-7, 1995.
  11. Biochemical evaluation and autoradiographic localization of the binding sites for the potent NK1 antagonist, [3H]LY303870.  DR Gehlert, DA Schober, JJ Howbert, J Nixon, BD Gitter, and PA Hipskind.  5th Annual European Neuropeptide Meeting, Lund, Sweden, June 3-7, 1995.
  12. Virtual screening as a tool for evaluating chemical libraries.  RF Bruns, RMA Simmons, JJ Howbert, DC Waters, PG Threlkeld, BD Gitter.  Exploiting Molecular Diversity: Small Molecule Libraries for Drug Discovery, La Jolla, CA, Jan. 23-25, 1995.
  13. Structure-activity relationships of the novel pyrazolidinone CCK antagonist LY262691.  Effects of substitution and replacement of the 4- and 5-phenyl groups.  JJ Howbert, KL Lobb, RF Brown, DA Neel, JK Reel, NR Mason, and LG Mendelsohn.  American Chemical Society, Chicago, IL, Aug. 22-27, 1993.
  14. CCK and schizophrenia: CCK-B antagonists inhibit dopamine neurons.  K Rasmussen, JF Czachura, ME Stockton, and JJ Howbert.  9th World Congress of Psychiatry, Rio de Janiero, Brazil, June 6-12, 1993.
  15. Anxiogenic effects of CCK agonists in a non-human primate model: central or peripheral?  RM Palmour, C Durieux, BP Roques, P Bertrand, M Capet, M-C Dubroeucq, JJ Howbert, G Woodruff, J Bradwejn, and FR Ervin.  CCK '93: International Symposium, Chatham, MA, May 19-22, 1993.
  16. Differential ability of a pyrazolidinone type A CCK receptor antagonist (LY219057) to block the gastric inhibitory and pyloric contractile actions of CCK.  JJ Howbert, GJ Schwartz, CF Salorio, KA Moore, and TH Moran.  CCK '93: International Symposium, Chatham, MA, May 19-22, 1993.
  17. CCK, schizophrenia, and anxiety: electrophysiological effects of CCK-B and CCK-A antagonists on midbrain dopamine neurons.  K Rasmussen, JF Czachura, ME Stockton, and JJ Howbert.  CCK '93: International Symposium, Chatham, MA, May 19-22, 1993.
  18. CCK-B receptors tonically modulate A10 dopaminergic neurons: neurochemical evaluation of LY288513.  S Iyengar, D Li, RM Simmons, JJ Howbert, and K Rasmussen.  CCK '93: International Symposium, Chatham, MA, May 19-22, 1993.
  19. CCK-8 contracts the gallbladder and colon through different mechanisms in the ferret.  S Mitan, J Howbert, and B Greenwood.  CCK '93: International Symposium, Chatham, MA, May 19-22, 1993.
  20. NK-1 receptor mediated anion transport in normal and inflamed guinea pig colon.  WE Albee, JJ Howbert, and JS Gidda.  American Gastroenterological Association, Boston, MA, May 16-19, 1993.
  21. Mechanisms by which CCK-8 stimulates gallbladder and colonic motility in the ferret.  S Mitan, P Prime, J Howbert, and B Greenwood.  American Gastroenterological Association, Boston, MA, May 16-19, 1993.
  22. Immunogenic inflammation augments tachykinin responsiveness of guinea pig trachealis: mediation through a neuronal release cascade?  RW Mitchell, IM Ndukwu, K Uzendowski, BD Gitter, JJ Howbert, J Solway, and AR Leff.  American Thoracic Society, May, 1993.
  23. LY288513, an antagonist of brain cholecystokinin (CCK-B) receptors, is active in preclinical models of anxiety, panic disorder, and schizophrenia.  JJ Howbert, RF Bruns, LG Mendelsohn, RM Palmour, JE Barrett, and K Rasmussen.  American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec. 14-18, 1992.
  24. Interleukin-6 secretion from the human astrocytoma cell line, U-373 MG, induced by substance P.  BD Gitter, DC Waters, D Regoli, AL Glasebrook, and JJ Howbert.  International Symposium on Substance P and Related Peptides, Shizuoka, Japan, Nov. 3-6, 1992.
  25. Histamine induces interleukin 6 release from the human astrocytoma cell line, U-373 MG.  DC Waters, RF Bruns, JJ Howbert, and BD Gitter.  Soc. Neurosci. Abstr. 18:482, 1992.
  26. Localization of receptors mediating effects of the selective CCK-B antagonist LY262691 on A9 and A10 dopamine cells: lesion and microinjection studies.  ME Stockton, JJ Howbert, and K Rasmussen.  Soc. Neurosci. Abstr. 18:278, 1992.
  27. Electrophysiological effects of diphenylpyrazolidinone CCK-B and CCK-A antagonists on A9 and A10 dopamine cells.  JF Czachura, JJ Howbert, and K Rasmussen.  Soc. Neurosci. Abstr. 18:278, 1992.
  28. The NK-1 receptor antagonist (+)-CP-96,345 produces biphasic changes in rat striatal dopamine release when administered via a microdialysis probe.  LA Phebus, JJ Howbert, and JA Nixon.  Soc. Neurosci. Abstr. 18:271, 1992.
  29. Inhibitory effects of an NK-1 (substance P) receptor antagonist, (+)-CP-96,345, on visceral nociceptive activity and non-nociceptive bladder activity in rats.  S Iyengar, MA Muhlhauser, JJ Howbert, and KB Thor.  Soc. Neurosci. Abstr. 18:271, 1992.
  30. Neurokinin-1 (NK-1) receptor blockade with (+/-) CP-96,345 inhibits hyperpnea-induced bronchoconstriction (HIB) in guinea pigs.  A Garland, JE Jordan, R Kao, B Gitter, J Howbert, J Necheles, and J Solway.  American Thoracic Society, Miami, FL, May 17-22, 1992.
  31. Inhibitory effects of an NK-1 (substance P) receptor antagonist, (+)-CP-96,345, on bladder activity and acetic acid-induced vesicoanal activity in rats.  KB Thor, MA Muhlhauser, JJ Howbert, and S Iyengar.  Society for Basic Urologic Research, Washington, D.C., May 8-9, 1992.
  32. The evaluation of candidate second generation diarylsulfonylurea oncolytics.  JE Toth, GB Grindey, WJ Ehlhardt, GB Boder, JL Zimmerman, JP McGrath, JJ Howbert, JR Bewley, KK Clingerman, SB Gates, CS Grossman, JE Ray, SM Rinzel, RM Schultz, LC Weir, JM Woodland, and JF Worzalla.  7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, Netherlands, Mar. 17-20, 1992.
  33. Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCK-B antagonist LY262691.  RM Palmour, FR Ervin, J Bradwejn, and JJ Howbert.  Soc. Neurosci. Abstr. 17:1602, 1991.
  34. Anxiolytic-like effects of the CCK-B antagonists LY262691, LY262684, and LY247348 on punished responding of squirrel monkeys.  JE Barrett, MC Linden, MJ Yu, and JJ Howbert.  Soc. Neurosci. Abstr. 17:1063, 1991.
  35. Species differences in brain neuropeptide receptor binding.  NR Mason, RF Bruns, JJ Howbert, and MJ Yu.  Soc. Neurosci. Abstr. 17:808, 1991.
  36. Potent antagonism of the feeding inhibitory actions of exogenous CCK-8 by a selective pyrazolidinone type A CCK receptor antagonist (LY219057).  JJ Howbert, NR Mason, RF Bruns, LA Netterville, GJ Schwartz, and TH Moran.  Soc. Neurosci. Abstr. 17:491, 1991.
  37. Pharmacological characterization of new neurokinin (substance P) antagonists.  N Rouissi, BD Gitter, JJ Howbert, D Jukic, and D Regoli.  American Society for Pharmacology and Experimental Therapeutics, San Diego, CA, Aug. 16-20, 1991.
  38. New non-peptide pyrazolidinone cholecystokinin (CCK) and gastrin antagonists.  JJ Howbert.  Joint Great Lakes-Central Regional Meeting of American Chemical Society, Indianapolis, IN, May 29-31, 1991.
  39. Evaluation of the mechanism of action of the diarylsulfonylurea, LY181984, using 2-D gel electrophoresis.  RL Merriman, GB Grindey, JJ Howbert, B Skidmore, and L Tanzer.  Proc. Am. Assoc. Cancer Res. 32:393, 1991.
  40. LY181984, a new diarylsulfonylurea with selective antitumor activity against Ha-ras, but not Ki-ras, transformed epithelial cells.  RL Merriman, GB Grindey, JJ Howbert, G Poore, K Shackelford, RA Swift, and LR Tanzer.  Proc. Am. Assoc. Cancer Res. 32:405, 1991.
  41. Evidence that gastrin receptors on AR4-2J cells are distinct from CCK-B receptors, using novel pyrazolidinone CCK antagonists.  JJ Howbert, KL Lobb, RF Brown, JK Reel, LG Mendelsohn, NR Mason, DF Mahoney, and RF Bruns.  Soc. Neurosci. Abstr. 16:82, 1990.
  42. LY262684, a novel pyrazolidinone CCK antagonist: studies of contraction in guinea pig ileum.  VL Lucaites, LG Mendelsohn, NR Mason, ML Cohen, KL Lobb, RF Brown, JK Reel, and JJ Howbert.  Soc. Neurosci. Abstr. 16:82, 1990.
  43. Antagonism of CCK-8 evoked excitation in the ventral medial nucleus of the mouse by a new non-peptide CCK-B antagonist, LY262691.  JP Hodgkiss, JS Kelly, and JJ Howbert.  Multiple Cholecystokinin Receptors - Progress Toward CNS Therapeutic Targets, Harlow, England, Sept. 20-22, 1990.
  44. Medicinal chemistry of a novel series of non-peptide, pyrazolidinone CCK and gastrin antagonists.  JJ Howbert, KL Lobb, RF Brown, JK Reel, DA Neel, NR Mason, and LG Mendelsohn.  Multiple Cholecystokinin Receptors - Progress Toward CNS Therapeutic Targets, Harlow, England, Sept. 20-22, 1990.
  45. 1-O-Alkylglycerols as inhibitors of phospholipase A2.  JJ Howbert, KL Lobb, CS Grossman, RL Merriman, LR Tanzer, KA Shackelford, PP Ho, and B Bertsch.  American Chemical Society, Boston, MA, Apr. 22-27, 1990.
  46. Protein kinase C from rat brain: characterization and inhibitor studies.  LG Mendelsohn, VL Lucaites, and JJ Howbert.  Society for Neuroscience, Toronto, Canada, Nov. 13-18, 1988.
  47. Molecular modeling of low energy conformations of Ac-trp-met-asp-phe-NH2 [Ac-CCK-4] via exhaustive conformational search, using Ac-(ala)4-NH2 as a generalized tetrapeptide template.  JJ Howbert.  CCK '88 - Symposium on Cholecystokinin, Cambridge, England, Aug. 31-Sept. 2, 1988.
  48. Modeling of the indolocarbazole class of kinase inhibitors - structural relationship to the common phosphate donor, adenosine triphosphate.  JJ Howbert.  Eli Lilly Modeling Conference, Indianapolis, IN, Oct. 1-2, 1987.
  49. Effects of various compounds on interleukin 1-mediated A375.6 human melanoma toxicity.  RM Schultz, RA Archer, JJ Howbert, and MG Altom.  Proc. Am. Assoc. Cancer Res. 28: 403, 1987.
  50. Further development of diarylsulfonylureas as novel anticancer drugs.  GB Grindey, GB Boder, CS Grossman, JJ Howbert, GA Poore, WN Shaw, GC Todd, and JF Worzalla.  Proc. Am. Assoc. Cancer Res. 28: 309, 1987.
  51. Inhibition of PAIII rodent prostatic adenocarcinoma growth and metastasis by a new sulfonylurea antitumor agent, LY181984.  BL Neubauer, KL Best, RL Goode, RL Merriman, MF Sarosdy, LR Tanzer, and JJ Howbert.  J. Urology 135: 42, 1986.
  52. Identification of diarylsulfonylureas as novel antitumor agents.  GB Grindey, GB Boder, RW Harper, JJ Howbert, GA Poore, BJ Reider, WN Shaw, GC Todd, and JF Worzalla.  Proc. Am. Assoc. Cancer Res. 27: 277, 1986.
PATENTS ISSUED (U.S.)
  1. US 8,524,702.  Substituted benzoazepines as toll-like receptor modulators. Howbert JJ, Dietsch G, Hershberg R, Burgess LE, Doherty GA, Eary CT, Groneberg RD, Jones Z.
  2. US 8,314,090.  Methods of synthesis of benzazepine derivatives. Howbert JJ, Kusukuntla VR, Tretyakov A, Nielsen N, Krasik P, Jiang J-L, Yang HW.
  3. US 8,242,106.  Toll-like receptor agonist formulations and their use. Howbert JJ, Duvvuri M, Hershberg R, Dietsch G.
  4. US 7,829,737.  Protein tyrosine phosphatase inhibitors and methods of use thereof.  Blaskovich MAT, Baughman T, Little T, Qabar M, Schultz LM, Hong F, Patt W, Nagula G, Gage JL, Howbert JJ.
  5. US 7,504,389.  Protein tyrosine phosphatase inhibitors and methods of use thereof.  Blaskovich MAT, Baughman T, Little T, Patt W, Qabar M, Schultz LM, Nagula G, Gage JL, Howbert JJ.
  6. US 7,176,310.  Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents.  Baughman TA, Boyce JP, Darwish I, Howbert JJ, Ihle NC, Jackson RW, Jeffrey SC, Maeda D, Yager KM.
  7. US 6,906,046.  Pharmaceutical uses and synthesis of benzobicyclooctanes.  Jackson RW, Darwish I, Baughman TA, Howbert JJ.
  8. US 6,815,214.  Pharmaceutical uses and synthesis of diketopiperazines.  Boyce JP, Howbert JJ, Tabone JC.
  9. US 7,642,344.  Methods and compositions for determining the sequence of nucleic acid molecules.  Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  10. US 7,247,434.  Methods and compositions for determining the sequence of nucleic acid molecules.  Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  11. US 7,052,846.  Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques.  Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  12. US 6,815,212.  Methods and compositions for enhancing sensitivity in the analysis of biological-based assays. Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  13. US 6,623,928.  Methods and compositions for determining the sequence of nucleic acid molecules.  Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  14. US 6,613,508.  Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques.  Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  15. US 6,444,422.  Computer method and system for correlating data. Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  16. US 6,312,893.  Methods and compositions for determining the sequence of nucleic acid molecules.  Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  17. US 6,027,890.  Methods and compositions for enhancing sensitivity in the analysis of biological-based assays. Van Ness J, Tabone JC, Howbert JJ, Mulligan JT.
  18. US 5,545,641.  Methods of inhibiting physiological conditions associated with an excess of bradykinin.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  19. US 5,514,675.  Naphthyl bradykinin receptor antagonists.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  20. US 6,255,494.  Benzimidazolyl neuropeptide Y receptor antagonists.  Britton TC, Bruns RF, Cantrell BE, Hipskind PA, Lobb KL, Nixon JA, Ornstein PL, Smith ECR, Zarrinmayeh H, Zimmerman DM, Nunes AM, Howbert JJ.
  21. US 5,663,192.  Heterocyclic neuropeptide Y receptor antagonists.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  22. US 5,567,715.  Methods of treating depression by inhibiting physiological conditions associated with an excess of neuropeptide Y.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  23. US 5,567,714.  Methods of treating obesity by inhibiting physiological conditions associated with an excess of neuropeptide Y.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  24. US 5,576,337.  Methods of treating anxiety by inhibiting physiological conditions associated with an excess of neuropeptide Y.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  25. US 5,562,862.  Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  26. US 5,504,094.  Use of benzothiophenes to treat pain due to an excess of neuropeptide Y.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  27. US 5,491,140.  Naphthyl tachykinin receptor antagonists to treat physiological conditions.  Bruns RF, Gehlert DR, Howbert JJ, Lunn WHW.
  28. US 6,869,957.  Non-peptide tachykinin receptor antagonists [diaminopropanes].  Cho SY, Crowell TA, Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr., Lobb KL, Muehl BS, Nixon JA.
  29. US 6,727,255.  Piperidinyl and piperazinyl tachykinin receptor antagonists.  Cho SY, Crowell TA, Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr., Lobb KL, Muehl BS, Nixon JA.
  30. US 6,403,577.  Hexamethyleneiminyl tachykinin receptor antagonists.  Cho SY, Crowell TA, Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr., Lobb KL, Muehl BS, Nixon JA.
  31. US 6,175,013.  Imidazolinyl tachykinin receptor antagonists [imidazolines].  Hipskind PA, Howbert JJ, Muehl BS.
  32. US 5,684,033.  Non-peptide tachykinin receptor antagonists [diaminopropanes].  Cho SY, Crowell TA, Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr., Lobb KL, Muehl BS, Nixon JA.
  33. US 5,670,499.  Non-peptide tachykinin receptor antagonists [diaminopropanes].  Cho SY, Crowell TA, Gitter BD, Hipskind PA, Howbert JJ, Krushinski JH Jr., Lobb KL, Muehl BS, Nixon JA.
  34. US 5,565,568.  2-Acylaminopropanamides as tachykinin receptor antagonists.  Cho SYS, Hipskind PA, Howbert JJ, Muehl BS, Nixon JA.
  35. US 5,643,926.  Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof.  Brown RF, Howbert JJ, Lobb KL, Neel DA, Reel JK, Greenwood B.
  36. US 5,399,565.  Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof.  Greenwood B, Helton DR, Howbert JJ, Mitan SJ, Rasmussen K.
  37. US 5,300,514.  Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof.  Brown RF, Howbert JJ, Lobb KL, Neel DA, Reel JK, Greenwood B.
  38. US 5,565,494.  Antitumor compositions and methods of treatment [aminophenylsulfonylureas].  Grindey GB, Grossman CS, Howbert JJ, Lobb KL, Ray JE, Toth JE.
  39. US 5,354,778.  Antitumor compositions and methods of treatment [trisubstituted phenylsulfonyl-ureas].  Ray JE, Toth JE, Howbert JJ.
  40. US 5,234,955.  Antitumor compositions and methods of treatment [trisubstituted phenylsulfonyl-ureas].  Ray JE, Toth JE, Howbert JJ.
  41. US 5,302,724.  Antitumor compositions and methods of treatment [thienylsulfonylureas].  Howbert JJ, Mohamadi F, Spees MM.
  42. US 6,147,115.  Antitumor compositions and methods of treatment [alkylsulfonylureas].  Crowell TA, Howbert JJ, Ward JS.
  43. US 5,216,026.  Antitumor compositions and methods of treatment [alkylsulfonylureas].  Crowell TA, Howbert JJ, Ward JS.
  44. US 5,116,874.  New N-(4-substituted phenylaminocarbonyl)-heterocyclylsulfonamide cmpds. - useful as anti-neoplastic agents.  Harper RW, Howbert JJ, Poore GA, Rieder BJ, Tao EVP.
  45. US 5,594,028.  Anti-tumor methods and compounds [cyclylphenylsulfonylureas].  Harper RW, Howbert JJ, Poore GA, Rieder BJ, Tao EVP, Aikins JA.